Global Nucleic Acid Therapeutics CDMO Market

Report ID : 1348 | Published : 2022-10-04 | Pages: 185 | Format: PDF/EXCEL

The Global Nucleic acid therapeutics CDMO Market size was valued at US$ 1.93 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 10.7% from 2022 to 2030. Nucleic acid therapeutics deal with nucleic acids (DNA and RNA) or other related chemical compounds. The nucleic acid therapeutics CDMO market is estimated to show high growth over the next few years, driven by the high application potential of nucleic acids for a variety of medical conditions. In addition, the increasing preference for personalized medicine also propels the market growth. Furthermore, continued research and development activities for manufacturing innovative nucleic acid therapeutics are forcing pharmaceutical companies to expand their businesses. Most companies focus on partnerships, acquisitions, collaborations, and mergers with contract development and manufacturing organizations (CDMOs) to seamlessly scale oligonucleotides from research to commercial manufacturing. Therefore, scaling up the products cost-effectively and efficiently from research to commercial quantities is a key challenge to CDMOs.

Other driving factors of the nucleic acid therapeutics CDMO market include the growing demand for nucleic acid therapeutics and the high prevalence of chronic and genetic diseases. Furthermore, advancements in nucleic acid technologies, a rise in R&D investments, increasing FDA approvals of nucleic acid therapeutics, and growing CDMO partnerships and acquisitions are expected to escalate the nucleic acid therapeutics CDMO market growth over the forecast years. However, mass production at low cost, lack of expertise in developing nucleic acid therapeutics, and supply chain challenges are anticipated to hinder the industry growth.

The nucleic acid therapeutics CDMO market is segmented by technology (Column-Based Method and Microarray-Based Method), products (Standard Nucleic Acid, Micro-Scale Nucleic Acid, Large-Scale Nucleic Acid, Custom Nucleic Acid, Modified Nucleic Acid, Primers, Probes, Other Nucleic Acid, and Other Services), end-users (Pharmaceutical Companies, Academic Research Institute, Diagnostic Laboratories), and geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa). North America holds the highest share of this market.

Some of the key players of Nucleic acid therapeutics CDMO market are Agilent Technologies, Inc., Ajinomoto Co. Inc., Bachem Holding AG., Biospring GmbH, Corden Pharma International, Danaher Corporation, Guangzhou Ruibo Biotechnology Co., Ltd., KNC Laboratories Co., Ltd., LGC Limited, Merck KGaA, Nippon Shokubai Co., Ltd., Nitto Denko Avecia Inc, QIAGEN N.V., ST Pharm Co Ltd, Sumitomo Chemical Co., Ltd., Syngene International Limited, Thermo Fisher Scientific Inc., Wuxi AppTec, Yamasa Corporation, Laboratorios Farmacéuticos Rovi, S.A., Sartorius AG (BIA Separations), AGC Biologics, FUJIFILM Diosynth Biotechnologies, Hanmi Pharmaceutical, Arranta Bio (Recipharm), ST Pharm, BioCina Pty Ltd., Curia Global, Inc. and Other Prominent Players.

 

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Nucleic Acid Therapeutics CDMO Market Snapshot

Chapter 4. Global Nucleic Acid Therapeutics CDMO Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Technology Estimates & Trend Analysis

5.1. By Technology & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Technology:

5.2.1. Column-Based Method

5.2.2. Microarray-Based Method

Chapter 6. Market Segmentation 2: By Products Estimates & Trend Analysis

6.1. By Products & Market Share, 2020 & 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Products:

6.2.1. Standard Nucleic Acid

6.2.2. Micro-Scale Nucleic Acid

6.2.3. Large-Scale Nucleic Acid

6.2.4. Custom Nucleic Acid

6.2.5. Modified Nucleic Acid

6.2.6. Primers

6.2.7. Probes

6.2.8. Other Nucleic Acid

6.2.9. Other Services 

Chapter 7. Market Segmentation 3: By End-user Estimates & Trend Analysis

7.1. By End-user & Market Share, 2020 & 2030

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By End-user:

7.2.1. Pharmaceutical Companies

7.2.2. Academic Research Institute

7.2.3. Diagnostic Laboratories

Chapter 8. Nucleic Acid Therapeutics CDMO Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) estimates and forecasts By Technology, 2020-2030

8.1.2. North America Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) estimates and forecasts By Products, 2020-2030

8.1.3. North America Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) estimates and forecasts by End-user, 2020-2030

8.1.4. North America Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) estimates and forecasts by country, 2020-2030

8.2. Europe

8.2.1. Europe Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) By Technology, 2020-2030

8.2.2. Europe Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) By Products, 2020-2030

8.2.3. Europe Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) estimates and forecasts by End-user, 2020-2030

8.2.4. Europe Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) by country, 2020-2030

8.3. Asia Pacific

8.3.1. Asia Pacific Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) By Technology, 2020-2030

8.3.2. Asia Pacific Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) By Products, 2020-2030

8.3.3. Asia Pacific Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) estimates and forecasts by End-user, 2020-2030

8.3.4. Asia Pacific Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) by country, 2020-2030

8.4. Latin America

8.4.1. Latin America Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) By Technology, (US$ Million)

8.4.2. Latin America Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) By Products, (US$ Million)

8.4.3. Latin America Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) estimates and forecasts by End-user, 2020-2030

8.4.4. Latin America Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) by country, 2020-2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) By Technology, (US$ Million)

8.5.2. Middle East & Africa Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) By Products, (US$ Million)

8.5.3. Middle East & Africa Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) estimates and forecasts by End-user, 2020-2030

8.5.4. Middle East & Africa Nucleic Acid Therapeutics CDMO Market revenue (US$ Million) by country, 2020-2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Agilent Technologies, Inc.

9.2.2. Ajinomoto Co. Inc.

9.2.3. Bachem Holding AG.

9.2.4. Biospring GmbH

9.2.5. Corden Pharma International

9.2.6. Danaher Corporation

9.2.7. Guangzhou Ruibo Biotechnology Co., Ltd.

9.2.8. KNC Laboratories Co., Ltd.

9.2.9. LGC Limited

9.2.10. Merck KGaA

9.2.11. Nippon Shokubai Co., Ltd.

9.2.12. Nitto Denko Avecia Inc.

9.2.13. QIAGEN N.V.

9.2.14. ST Pharm Co Ltd

9.2.15. Sumitomo Chemical Co., Ltd.

9.2.16. Syngene International Limited

9.2.17. Thermo Fisher Scientific Inc.

9.2.18. Wuxi AppTec

                9.2.19.  Yamasa Corporation

                9.2.20.  Laboratorios Farmacéuticos Rovi, S.A.

                9.2.21.  Sartorius AG (BIA Separations)

                9.2.22.  AGC Biologics

                9.2.23.  FUJIFILM Diosynth Biotechnologies

                9.2.24.  Hanmi Pharmaceutical

                9.2.25.  Arranta Bio (Recipharm)

                9.2.26.  ST Pharm

                9.2.27.  BioCina Pty Ltd.

                9.2.28.  Curia Global, Inc.

                9.2.29.  Other Prominent Players

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Technology

  • Column-Based Method
  • Microarray-Based Method

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Products

  • Standard Nucleic Acid
  • Micro-Scale Nucleic Acid
  • Large-Scale Nucleic Acid
  • Custom Nucleic Acid
  • Modified Nucleic Acid
  • Primers
  • Probes
  • Other Nucleic Acid
  • Other Services

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on End-Users

  • Pharmaceutical Companies
  • Academic Research Institute
  • Diagnostic Laboratories

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 based on Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America nucleic acid therapeutics CDMO market revenue (US$ Million) by Country, 2020 to 2030

  • U.S.
  • Canada

Europe nucleic acid therapeutics CDMO market revenue (US$ Million) by Country, 2020 to 2030

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific nucleic acid therapeutics CDMO market revenue (US$ Million) by Country, 2020 to 2030

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America nucleic acid therapeutics CDMO market revenue (US$ Million) by Country, 2020 to 2030

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa nucleic acid therapeutics CDMO market revenue (US$ Million) by Country, 2020 to 2030

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Landscape

  • Company Overview
  • Financial Performance
  • Key Development

Latest Strategic Developments

Companies Mentioned

  • Agilent Technologies, Inc.
  • Ajinomoto Co. Inc.
  • Bachem Holding AG.
  • Biospring GmbH
  • Corden Pharma International
  • Danaher Corporation
  • Guangzhou Ruibo Biotechnology Co., Ltd.
  • KNC Laboratories Co., Ltd.
  • LGC Limited
  • Merck KGaA
  • Nippon Shokubai Co., Ltd.
  • Nitto Denko Avecia Inc.
  • QIAGEN N.V.
  • ST Pharm Co Ltd
  • Sumitomo Chemical Co., Ltd.
  • Syngene International Limited
  • Thermo Fisher Scientific Inc.
  • Wuxi AppTec
  • Yamasa Corporation
  • Laboratorios Farmacéuticos Rovi, S.A.
  • Sartorius AG (BIA Separations)
  • AGC Biologics
  • FUJIFILM Diosynth Biotechnologies
  • Hanmi Pharmaceutical
  • Arranta Bio (Recipharm)
  • ST Pharm
  • BioCina Pty Ltd.
  • Curia Global, Inc.
  • Other Prominent Players

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?

Frequently Asked Questions

Who are the Key Players in the Global Nucleic acid therapeutics CDMO Market?

US$ 1.93 billion in 2021

annual growth rate (CAGR) of 10.7% from 2022 to 2030

Our Clients